O
OnKure Therapeutics, Inc. (OKUR)
NGM – Real Time Price. Currency in USD
3.39
-0.05 (-1.45%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
3.39
-0.05 (-1.45%)
At close: May 12, 2026, 4:00 PM EDT
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
| Name | Position |
|---|---|
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer |
| Dr. Isaac Manke Ph.D. | Senior VP of Business Development & Director |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry |
| Dr. Nicholas A. Saccomano Ph.D. | President, CEO & Director |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
| Mr. Jason A. Leverone CPA | Chief Financial Officer |
| Mr. Rogan P. Nunn J.D. | General Counsel & Secretary |
| Ms. Roberta Alton | Senior Vice President of Clinical Operations |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 8-K | okur-20260505.htm |
| 2026-04-24 | S-3 | d122209ds3.htm |
| 2026-04-21 | DEFA14A | ny20066577x2_defa14a.htm |
| 2026-03-30 | 8-K | d910791d8k.htm |
| 2026-03-12 | S-8 | okur-20260312.htm |
| 2025-11-06 | S-3 | d46696ds3.htm |
| 2025-08-12 | 8-K | okur-20250812.htm |
| 2025-06-26 | 8-K | okur-20250626.htm |
| 2025-05-28 | 8-K | okur-20250527.htm |
| 2025-04-16 | DEFA14A | ny20043636x2_defa14a.htm |